EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023

Jul 12, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-07-10

Reporting Person: Lurker Nancy (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-07-10	Restricted Stock Units	$0.00	A	33334.00	Acquired		Common Stock (33334.00)	Direct
2023-07-10	Stock Option (Right to Buy)	$9.11	A	66666.00	Acquired	2033-07-10	Common Stock (66666.00)	Direct

Footnotes

F1: The restricted stock units will vest in three ratable annual installments beginning July 10, 2024.

F2: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months